A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma
Phase of Trial: Phase I/II
Latest Information Update: 10 Oct 2019
Price : $35 *
At a glance
- Drugs Carotuximab (Primary) ; Pazopanib
- Indications Haemangiosarcoma; Soft tissue sarcoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors TRACON Pharmaceuticals
- 04 Oct 2019 Status changed from active, no longer recruiting to completed.
- 09 Nov 2018 Planned End Date changed from 1 Dec 2018 to 1 Mar 2020.
- 09 Nov 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Mar 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History